Thermo Fisher Scientific Inc.: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 3, 2023 and accepted by EDGAR at Nov 3, 2023, 13:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-02 to 2023-09-30 | $10.57bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-01-01 to 2023-09-30 | $31.97bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2023-07-02 to 2023-09-30 | $319.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-01-01 to 2023-09-30 | $1.01bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-07-02 to 2023-09-30 | $2.05bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2023-01-01 to 2023-09-30 | $6.31bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-07-02 to 2023-09-30 | $1.86bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-01-01 to 2023-09-30 | $5.00bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-07-02 to 2023-09-30 | $359.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2023-01-01 to 2023-09-30 | $985.0m | us-gaap:InterestExpense |
| Income tax | 3 months2023-07-02 to 2023-09-30 | $53.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-01-01 to 2023-09-30 | $151.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-02 to 2023-09-30 | $1.70bn | us-gaap:ProfitLoss |
| Net income | 9 months2023-01-01 to 2023-09-30 | $4.35bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2023-07-02 to 2023-09-30 | $4.42 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-01-01 to 2023-09-30 | $11.25 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-02 to 2023-09-30 | $4.44 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-01-01 to 2023-09-30 | $11.31 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-02 to 2023-09-30 | 388,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-01-01 to 2023-09-30 | 388,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-01-01 to 2023-09-30 | $4.68bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-01-01 to 2023-09-30 | $1.07bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2023-01-01 to 2023-09-30 | $387.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2023-01-01 to 2023-09-30 | $3.00bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-09-30 | $6.15bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $23.09bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $97.06bn | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $14.16bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2023-09-30 | $35.08bn | us-gaap:LongTermDebt |
| Current portion of debt | At period end2023-09-30 | $4.79bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2023-09-30 | $45.33bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2023-09-30 | 386,372,321 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000097745-23-000069. Last ingested by Listed: Nov 6, 2026, 03:40 ET. Listed shows no prices and gives no investment advice.